139 results about "Alternative splicing" patented technology

Alternatively spliced RNA, along with their normally-spliced counterparts, can be rapidly identified by hybridizing cDNA from normal tissue to cDNA from an abnormal or test tissue. The two cDNA populations are separately tagged prior to hybridization, which allows isolation of double-stranded cDNA containing both normal and alternatively spliced molecules. Within this population, pairing of cDNA molecules representing an alternatively spliced mRNA with cDNA molecules representing the counterpart normally spliced mRNA will form double-stranded cDNA with single-stranded mismatched regions. The mismatched double-stranded cDNA are isolated with reagents that bind single-stranded nucleic acids. The strands of each mismatched double-stranded cDNA are then coupled and analyzed, simultaneously identifying both normal and alternatively spliced molecules.

The present invention relates to antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal. Exemplary antisense antiviral compounds are substantially uncharged, or partially positively charged, morpholino oligonucleotides having 1) a nuclease resistant backbone, 2) 12-40 nucleotide bases, and 3) a targeting sequence of at least 12 bases in length that hybridizes to a target region selected from the following: a) the 5′ or 3′ terminal 25 bases of the negative sense viral RNA segment of Influenzavirus A, Influenzavirus B and Influenzavirus C; b) the terminal 30 bases of the 5′ or 3′ terminus of the positive sense vcRNA; c) the 45 bases surrounding the AUG start codon of an influenza viral mRNA and; d) 50 bases surrounding the splice donor or acceptor sites of influenza mRNAs subject to alternative splicing.

The present invention relates to antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal. Exemplary antisense antiviral compounds are substantially uncharged, or partially positively charged, morpholino oligonucleotides having 1) a nuclease resistant backbone, 2) 12-40 nucleotide bases, and 3) a targeting sequence of at least 12 bases in length that hybridizes to a target region selected from the following: a) the 5′ or 3′ terminal 25 bases of the negative sense viral RNA segment of Influenzavirus A, Influenzavirus B and Influenzavirus C; b) the terminal 30 bases of the 5′ or 3′ terminus of the positive sense vcRNA; c) the 45 bases surrounding the AUG start codon of an influenza viral mRNA and; d) 50 bases surrounding the splice donor or acceptor sites of influenza mRNAs subject to alternative splicing.

The invention relates to methods, reagents and apparatus for detecting protein isoforms (e.g., those due to alternative splicing, or different disease protein isoforms or degradation products) in a sample, including using combinations of capture agents to identify the isoforms to be detected / measured.

The invention described herein relates to an RNA-based control device that senses the presence and / or concentration of at least one protein ligand, preferably through its protein-binding aptamer domain, and regulates a target gene expression through alternative splicing of the target gene in which the RNA-based control device is integrated. The device has uses in therapeutic as well as diagnostic applications.

The invention relates to methods, reagents and apparatus for detecting protein isoforms (e.g., those due to alternative splicing, or different disease protein isoforms or degradation products) in a sample, including using combinations of capture agents, each combination being unique to the splicing variant to be detected / measured.

The invention discloses a preparation method of a sea cucumber polypeptide. The method comprises the following steps: screening raw materials; cleaning the raw materials; carrying out low-temperature enzymolysis; carrying out first concentration filtration; carrying out second concentration filtration; and drying. The reaction condition in the whole preparation process disclosed by the invention is mild; and the activity of the sea cucumber polypeptide can be ensured. Low-temperature enzymolysis at 40-60 DEG C is adopted, and enzyme cutting sites of sea cucumber protein is subjected to alternative splicing through papain and collagenase, so that the enzymolysis of the sea cucumber protein is relatively thorough; and the sea cucumber protein with high molecular weight is decomposed into a plurality of micro-molecule polypeptides with smaller molecular weight, so that the absorption requirements of a human body are met, full absorption of the human body on the sea cucumber polypeptide is facilitated, and the absorptivity can reach over 80%. The sea cucumber polypeptide prepared by the method disclosed by the invention is very low in harmful heavy metal ion content, and safe and non-toxic. The preparation method disclosed by the invention is low in wastewater discharge in the preparation process and beneficial to reduction of energy consumption, is capable of utilizing the value of the sea cucumber to the maximal extent, and has important social and economic significance.

The invention provides a eucaryon alternative splicing analysis method and system based on RNA-seq data. The method comprises the steps that transcriptome original sequencing data of one or more samples of a certain eucaryon with a reference genome and annotation is acquired through an illumina next-generation sequencing platform; unqualified data is filtered out, and the remaining data serves asto-be-analyzed data; next, basic analysis is performed, wherein the to-be-analyzed data of all the transcriptome samples is compared to the reference genome of the species, and a unique comparison result is screened out; expression quantities of all sample genes are calculated; the genes with significant difference expression are screened out; functional annotation and analysis are performed on the differential genes; then alternative splicing analysis is performed, wherein a known alternative splicing event is identified; a new alternative splicing event is identified; the difference betweenalternative splicing events of samples (sample groups) is analyzed; the correlation between alternative splicing and gene expression is analyzed; the alternative splicing analysis result is subjectedto statistical analysis, and a report is generated; and an alternative splicing visual graph is generated.

The invention relates to methods, reagents and apparatus for detecting protein isoforms (e.g., those due to alternative splicing, or different disease protein isoforms or degradation products) in a sample, including using combinations of capture agents to identify the isoforms to be detected / measured.

The present invention concerns six novel variants of alternative splicing of the CD40 receptorThe invention provides a pharmaceutical composition comprising a gastrin compound having an extended activity upon administration to a subject in comparison with native gastrin. Methods are provided of conjugating portions of the amino acid sequence of gastrin having functional ability to bind to the gastrin / CCK receptor, to various carrier moieties, including the use of amino acid spacer regions, and use of bifunctional cross-linking reagents. Methods of treating a diabetes patient with the compositions are provided.

Disclosed are novel splicing variants of the genes associated with prostate cancer risk and survival, particularly splicing variants of PIK3CD, FGFR3, TSC2, RASGRP2, ITGA4, MET, NF1 and BAK1. The disclosure also relates risk assessment, detection, diagnosis, or prognosis of prostate cancer. More specifically, this disclosure relates to the detection of certain splicing variants of PIK3CD, FGFR3, TSC2, RASGRP2, ITGA4, MET, NF1 and BAK1.

The invention provides isolated polynucleotides and their encoded proteins that are involved in splicing or modulating splicing activity. The invention further provides recombinant expression cassettes, host cells, transgenic plants, and antibody compositions. The present invention provides methods and compositions relating to altering splicing protein content and / or composition of plants.

Methods for treatment and diagnosis of neurological disorders such as autism and autism spectrum disorder are disclosed. Also disclosed are modulators of alternative splicing regulators SRRM4 and / or SRRM3 for treating neurological disorders. Further disclosed are agents that modulate the expression of at least one splice variant for treating neurological disorders. Mouse models of neurological disorders having increased or decreased expression of SRRM4 and / or SRRM3 are also disclosed.